ACTAVIS Group has partnered with QRxPharma Limited to launch a patented 3:2 ratio fixed dose combination of morphine and oxycodone, MoxDuo, into the US$2.5 billion American acute pain market. MoxDuo is now expected to hit the US market in the third quarter of 2012.
The above article was sent to subscribers in Pharmacy Daily's issue from 23 Dec 11
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Dec 11
